ライフサイエンスコーパス: GVL effect

1 f EL4 cells and B10.BR DLI had a more modest GVL effect.

2 utologous BMT may be a means for providing a GVL effect.

3 ty Ag (miHAg) with a proven role in GVHD and GVL effect.

4 GVHD but eliminates, at least partially, the GVL effect.

5 hality can be mitigated without negating the GVL effect.

6 ceived AML alone, demonstrating a functional GVL effect.

7 in an Ag-dependent manner while sparing the GVL effect.

8 sulting in the concomitant inhibition of the GVL effect.

9 ockade of NKG2D significantly suppressed the GVL effect.

10 or GVHD induction while less critical to the GVL effect.

11 (-/-)) Tconv mediate a robust and beneficial GvL effect.

12 T cells attack leukemia cells, mediating the GVL effect.

13 3 signaling reduces GVHD without loss of the GVL effect.

14 e in WT1 expression, suggesting a WT1-driven GVL effect.

15 monstrated that perforin is critical for the GVL effect.

16 and Th17 response, and preserved beneficial GVL effects.

17 ts effective GVHD protection while enhancing GVL effects.

18 n increase of ISCs and PCs without impairing GVL effects.

19 KCalpha spared T-cell cytotoxic function and GVL effects.

20 ng particularly on enhancing the therapeutic GVL effects.

21 tologic malignancies through T cell-mediated GVL effects.

22 ecognition for preventing GVHD while sparing GVL effects.

23 xhaustion, or apoptosis, resulting in strong GVL effects.

24 to host antigens and maintaining beneficial GVL effects.

25 y administration of DLI can mediate powerful GVL effects.

26 n approach to inhibiting GVHD that optimizes GVL effects.

27 a STAT6-dependent mechanism while preserving GVL effects.

28 e T cells mediate the graft-versus-leukemia (GVL) effect.

29 IL-11 can maintain a graft-versus-leukemia (GVL) effect.

30 s (DLIs) enhances the graft-versus-leukemia (GVL) effect.

31 cells, the so-called graft-versus-leukemia (GVL) effect.

32 greatly relies on the graft-versus-leukemia (GVL) effect.

33 eserving a beneficial graft-versus-leukemia (GVL) effect.

34 recipient and mediate the graft-vs-leukemia (GVL) effect.

35 VHD while sparing the graft-versus-leukemia (GVL) effect.

36 or a cancer-specific graft-versus-leukemia (GVL) effect.

37 ity, resulting in the graft-versus-leukemia (GVL) effect.

38 demonstration of the graft-versus-leukemia (GVL) effect.

39 c and fail to mediate graft-versus-leukemia (GVL) effects.

40 e mediated allogeneic graft-versus-leukemia (GVL) effects.

41 capable of providing graft-versus-leukemia (GVL) effects.

42 GVHD while preserving graft-versus-leukemia (GVL) effects.

43 (TIM-3) for improving graft-versus-leukemia (GVL) effects.

44 reactive and mediate graft-versus-leukemia (GVL) effects.

45 that does not impair graft-versus-leukemia (GVL) effects.

46 The therapeutic GVL effect after allogeneic stem cell transplantation is

47 to respond to virus infection and to induce GVL effect after BMT.

48 CD45 epitopes may be useful in restoring the GVL effect after HLA-A2-mismatched haploidentical transp

49 Natural killer (NK) cells mediate GVL effects after allogeneic hematopoietic cell transpla

50 that perforin is a crucial pathway mediating GVL effects after G-CSF-mobilized PBSCT.

51 WT1) contributes to a graft-versus-leukemia (GVL) effect after allogeneic stem-cell transplantation (

52 ctivity and preserved graft-versus-leukemia (GVL) effects after allogeneic BMT (70% vs 10%; P <.01).

53 ounterparts; however, graft-versus-leukemia (GVL) effects after allogeneic stem cell transplantation

54 Furthermore, IFN-gamma is involved in the GVL effect against EL4 leukemia, demonstrating that prot

55 n the Y chromosome contribute to a selective GVL effect against myeloid and lymphoid leukemias after

56 GVL effects against EL4 depended on CD8-mediated allorea

57 ost lymphohematopoietic reactions, including GVL effects against host leukemia/lymphoma cells, of CD8

58 In contrast, DNAM-1 was not critical for GVL effects against ligand (CD155) expressing and nonexp

59 ut did not abrogate a graft-versus-leukemia (GVL) effect against C1498, a myeloid leukemia.

60 t donor CD8-dependent graft-versus-leukemia (GVL) effects against EL4 (H-2(b)) leukemia/lymphoma can

61 on of TK-transduced T lymphocytes may induce GVL effect and allow for their subsequent selective elim

62 Both GVL effects and the inhibitory effect of IL-12 on GVHD w

63 event relapse via the graft-versus-leukemia (GVL) effect and are critical for responding against oppo

64 8+ T cells mediate both a graft-vs-leukemia (GVL) effect and graft-vs-host disease (GVHD).

65 ad to an insufficient graft-versus-leukemia (GVL) effect and relapse.

66 s may contribute to a graft-versus-leukemia (GVL) effect and to graft-versus-host disease (GVHD).

67 The graft-versus-leukemia (GVL) effects and graft-versus-host disease (GVHD)-induci

68 atibility, graft-versus-host disease (GVHD), GVL effect, and immune reconstitution after transplant.

69 on, but GVHD is tightly linked to beneficial GVL effects, and removal of donor T cells that cause GVH

70 uggesting that anti-TIM-3 treatment-mediated GVL effects are Tc induced.

71 ty and the beneficial graft-versus-leukemia (GVL) effect, as well as the impairment of immune reconst

72 The graft-versus-leukemia (GVL) effect associated with allogeneic blood and marrow

73 s through T-cell-mediated graft-vs-leukemia (GVL) effects but often leads to severe graft-vs-host dis

74 ing donor cell engraftment and improving the GVL effect, but they should not recognize host nonhemato

75 on can provide a curative graft-vs-leukemia (GVL) effect, but there is a significant risk of graft-vs

76 vely augment T-cell responses that promote a GVL effect by adoptive immunotherapy with T-cell clones

77 iller (NK) cells can be recruited to mediate GVL effect by careful mismatching on the killer-cell imm

78 Augmenting the GVL effect by the adoptive transfer of donor-derived B-A

79 empted to improve the graft-versus-leukemia (GVL) effect by generating allorestricted cytotoxic T lym

80 ell-mediated graft-versus-leukemia/lymphoma (GVL) effects, derived from the graft or subsequent adopt

81 sex combinations, demonstrating a selective GVL effect distinct from that contributed by GVHD.

82 treatment with HY-iTregs still preserved the GVL effect even against pre-established leukemia.

83 st disease (GVHD) and graft-versus-leukemia (GVL) effects following bone marrow transplantation (BMT)

84 t that T cell Stat3 deficiency can extricate GVL effects from GVHD through tissue-specific programmed

85 offers a novel approach to the separation of GVL effects from GVHD.

86 pproach to separating graft-versus-lymphoma (GVL) effects from graft-versus-host disease (GVHD) in mi

87 The most direct evidence of the GVL effect has been provided by the efficacy of donor le

88 A graft-versus-leukemia (GVL) effect has been considered a major factor responsib

89 The intrinsic graft-versus-leukemia (GvL) effect, however, is the desirable curative benefit.

90 whether G-CSF-mobilized PBSC maintain their GVL effect in a murine allogeneic transplant model (B6 -

91 The graft-versus-leukemia (GVL) effect in allogeneic hematopoietic stem cell transp

92 ens implicated in the graft-versus-leukemia (GVL) effect in chronic myeloid leukemia (CML) include WT

93 ells and enhanced the graft-versus-leukemia (GVL) effect in human xenograft models.

94 hout compromising the graft-versus-leukemia (GVL) effect in lymphocytic and myeloid leukemia mouse mo

95 er IL-18 can maintain graft-versus-leukemia (GVL) effect in this context.

96 ile preserving strong graft-versus-leukemia (GVL) effects in allogeneic and xenogeneic murine GVHD mo

97 y, IFN-gamma enhances graft-versus-leukemia (GVL) effects in both models.

98 without compromising graft-versus-leukemia (GVL) effects in multiple mouse models.

99 els and reduces acute GVHD while maintaining GVL-effects, including in corticosteroid-refractory sett

100 The GVL effect is directed against minor histocompatibility

101 separation of GVL from GVHD, suggesting the GVL effect is due to largely unopposed Tcon alloantigen

102 e not selected for leukemia specificity, the GVL effect is often accompanied by life-threatening graf

103 h preservation of the graft-versus-leukemia (GVL) effect is a crucial step to improve the overall sur

104 ) without loss of the graft-versus-leukemia (GVL) effect is the holy grail of hematopoietic cell tran

105 suggest that donor-derived NK cell-mediated GVL effects may be improved by sensitizing residual quie

106 The late loss of DLI-mediated GVL effects may reflect the eventual loss of donor-deriv

107 days) was more potent than the Tc2-mediated GVL effect (mean survival of 20.5 days; Tc1 > Tc2, p = 0

108 doses of 2 to 2.5 x 10(7), the Tc1-mediated GVL effect (mean survival of 34.2 days) was more potent

109 majority of mixed chimeras, with significant GvL effects mediated by both CD4(+) and CD4(-) cells.

110 GVL effects mediated by granzyme-positive CD8 T cells we

111 ignancies is due to a graft-versus-leukemia (GVL) effect mediated by donor T cells that recognize rec

112 The graft-versus-leukemia (GVL) effect mediated by the allogeneic graft, however, i

113 erapy and from potent graft-versus-leukemia (GVL) effects mediated by donor immunity.

114 The graft-versus-leukemia (GVL) effect, mediated by donor T cells, has revolutioniz

115 atory mechanisms involved in restraining the GVL effect must be better deciphered in humans.

116 Finally, we found that the in vivo GVL effect of CD18-/- donor T cells was largely preserve

117 iously unidentified means for augmenting the GVL effect of delayed donor lymphocyte infusion.

118 dministration of anti-B7 mAbs may impair the GVL effect of DLI and that the forced expression of B7-1

119 of B7-1 on EL4 cells markedly augmented the GVL effect of DLI, in contrast to the forced expression

120 e first time that GVHD-inducing activity and GVL effects of allogeneic CD8 T cells can be separated b

121 icant protective effect against GVHD, marked GVL effects of allogeneic T cells against EL4 were obser

122 approach to inhibiting GVHD while preserving GVL effects of alloreactivity.

123 The graft-versus-leukemia (GVL) effect of donor cells (against A20 tumor cells) was

124 on, and IFN-gamma production while enhancing GVL effects, preventing Tc exhaustion, and improving Tc

125 Conversely, CD8(+) T cells induce GVL effects primarily through the use of perforin and mi

126 , and treatment approaches to manipulate the GVL effect remain limited.

127 cking antibodies are not only possible novel GVL effect-sparing therapeutics for the treatment of GVH

128 of the biology of the graft-versus-leukemia (GVL) effect still lags behind that of GVHD, and treatmen

129 l-recognized graft-versus-leukemia/lymphoma (GVL) effect that is mediated by donor-derived alloreacti

130 T cells mediate this graft-versus-leukemia (GVL) effect, the influence of DLI on the T cell compartm

131 risk leukemia through graft-versus-leukemia (GVL) effects, the process by which malignant leukemic ce

132 from the failure of a graft-versus-leukemia (GVL) effect to eradicate minimal residual disease.

133 n (BMT) relies on the graft-versus-leukemia (GVL) effect to eradicate residual tumor cells through im

134 ation, leveraging the graft-versus-leukemia (GvL) effect to restore immune control.

135 Prevention of GVHD while preserving GVL effect using third-party regulatory T cells is under

136 -TIM-3 treatment as a strategy for enhancing GVL effects via metabolic and transcriptional Tc reprogr

137 indicate that menin-inhibition enhances the GVL-effect via the HERV/MHC-II axis in AML cells and pro

138 The magnitude of the GVL effect was dependent on the level of major histocomp

139 eficient donor T cells demonstrated that the GVL effect was perforin dependent.

140 ma challenge model, a graft-versus-lymphoma (GVL) effect was fully retained when anti-human VISTA mAb

141 asoning that AZA might selectively augment a GVL effect, we studied the immunologic sequelae of AZA a

142 The problem of harnessing GVL effects while controlling inflammation and host-orga

143 igate strategies that retain and enhance the GVL effects while limiting toxicity from this therapy, a

144 uvers to optimize the graft-versus-leukemia (GVL) effect while preventing graft-versus-host-disease (

145 full donor chimerism and mediated a powerful GVL effect with complete protection (100% survival) agai

146 infusion (DLI) post-BMT can mediate a potent GVL effect with less graft-vs-host disease (GVHD) than w

147 ll subsets mediated a graft-versus-leukemia (GVL) effect with reduced graft-versus-host disease (GVHD

148 ansplantation as a mechanism of augmenting a GVL effect without a concomitant increase in GVHD.

149 rced expression of B7-1 ligands stimulates a GVL effect without adversely affecting the GVHD lethalit

150 Strategies that augment a GVL effect without increasing the risk of GVHD are requi

151 donor lymphocyte infusions (DLI) to mediate GVL effects without GVHD in mixed chimeras prepared with

152 ons (DLIs) can induce graft-versus-leukemia (GVL) effects without graft-versus-host disease (GVHD).

153 h to achieve graft-versus-leukemia/lymphoma (GVL) effects without GVHD, we have observed surprisingly